12 completed, 5 withdrawn, 4 terminated, 1 unknown. 22 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 12, Withdrawn 5, Terminated 4, Unknown 1 |
| Phase 2 | 9 | Withdrawn 4, Completed 3, Terminated 2 |
Follow devimistat: new trials by email Literature Review of devimistat trials Research Report on devimistat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas Devimistat, Modified FOLFIRINOX - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2023-07-01 | 2023-08-02 | |
| CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer CPI-613, modified FFX, Bevacizumab - C04.588.274.476.411.307 | Phase 1 | Withdrawn | Cornerstone Pharmaceuticals | 2023-03-30 | 2023-09-13 | |
| CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma CPI-613® (Dose level -1.0 250 mg/m^2), CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2) - Pancreas Adenocarcinoma | Phase 1 | Terminated | Medical College of Wisconsin | 8 | 2022-10-31 | 2025-11-12 |
| To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue CPI-613 + Hydroxychloroquine - Sarcoma, Clear Cell | Phase 1 / Phase 2 | Completed | Cornerstone Pharmaceuticals | 16 | 2021-09-01 | 2023-05-24 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) CPI 613, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 75 | 2020-06-23 | 2025-12-31 |
| CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer CPI 613, Oxaliplatin, Irinotecan - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | David Bajor, MD | 49 | 2018-12-07 | 2025-01-23 |
| CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study - Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2018-06-01 | 2018-08-01 | |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer CPI 613 in Combination With Gemcitabine and Nab-paclitaxel - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 | Unknown | Atlantic Health System | 24 | 2017-10-19 | 2018-02-19 |
| 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Daunorubicin Hydrochloride - Untreated Adult Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2015-12-01 | 2018-07-03 | |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation - Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 48 | 2015-09-01 | 2024-09-19 |
| CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery 6,8-bis(benzylthio)octanoic acid, fluorouracil, pharmacological study - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 1 | Completed | Wake Forest University Health Sciences | 19 | 2015-01-06 | 2023-08-07 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer 6,8-bis(benzylthio)octanoic acid - Recurrent Small Cell Lung Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 15 | 2013-10-01 | 2018-07-03 |
| CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer 6,8-bis(benzylthio)octanoic acid - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1 | Completed | Wake Forest University Health Sciences | 10 | 2013-07-01 | 2018-12-27 |
| CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery 6,8-bis(benzylthio)octanoic acid - Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 1 / Phase 2 | Completed | Wake Forest University Health Sciences | 17 | 2013-05-01 | 2019-05-15 |
| CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1 | Completed | Wake Forest University Health Sciences | 21 | 2013-04-01 | 2023-07-12 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia CPI-613, cytarabine, mitoxantrone hydrochloride - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Wake Forest University Health Sciences | 67 | 2013-01-01 | 2018-07-03 |
| Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies CPI-613 - Advanced Hematologic Malignancies | Phase 1 | Completed | Wake Forest University Health Sciences | 26 | 2010-03-01 | 2018-07-02 |
Showing 20 of 22. Sign in to see all of them.
Pancreatic Neoplasms (5) · Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Mycosis Fungoides (2) · Neoplasms (2) · Sezary Syndrome (2) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Congenital Abnormalities (1) · Disease Progression (1)
Wake Forest University Health Sciences (13) · Cornerstone Pharmaceuticals (4) · University of Michigan Rogel Cancer Center (2) · Atlantic Health System (1) · David Bajor, MD (1) · Medical College of Wisconsin (1)
United States (21) · Canada (1)
Caio Rocha Lima, MD (4) · Avi Retter, M.D. (2) · Timothy Pardee (2) · Angela T Alistar, MD (1) · Bayard Powell (1) · Bayard Powell, MD (1) · David Bajor, MD (1) · Divis K Khaira, M.D. (1) · Jimmy Ruiz (1) · Karen Gelmon, M.D. (1) · Mandana Kamgar, MD, MPH (1) · Neil Senzer, M.D. (1) · Rakhee Vaidya (1) · Senzer Neil, M.D. (1) · Stefan Grant (1)
PMID 25165100, PMID 28495639, PMID 35354808, PMID 36479231, PMID 37678921
P30CA012197 (11)